Zinecard (generic name, dexrazoaxane) is a cardioprotective drug that may be given to some breast cancer patients undergoing chemotherapy treatment with either of the anthracycline drugs, doxorubicin or epirubicin.[1]
Use of Zinecard has demonstrated the ability to reduce the risk of severe heart problems that may arise as a side effect of treatment with doxorubicin or epirubicin. Therefore, Zinecard treatment allows the risk of cardiotoxicity to be lowered in breast cancer patients who:[1]
• Need greater cumulative doses of doxorubicin or epirubicin
• Have pre-existing risk factors for heart disease and are going to receive doxorubicin or epirubicin treatment
REFERENCE
1. National Cancer Institute. Physicians Data Query: Breast cancer treatment. Accessed at www.cancer.gov.
|
is a trademark of HC Search Corporation.
for free.
